By Advocate.com Editors
Originally published on Advocate.com September 07 2002 12:00 AM ET
Durham, N.C.-based Triangle Pharmaceuticals on Wednesday applied for Food and Drug Administration marketing approval for its HIV nucleoside reverse transcriptase inhibitor Coviracil. "We believe that once approved, the potency, once-daily dosing, and pharmacokinetic profile of Coviracil will offer patients and physicians an important new tool in the management of HIV disease," said Triangle CEO Daniel Welch. The company also plans to apply soon for European marketing approval of the drug.